Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs

Milo Gatti,Massimo Andreoni,Federico Pea,Pierluigi Viale

DOI: https://doi.org/10.2147/DDDT.S313756

2021-08-03

Abstract:Milo Gatti, 1, 2 Massimo Andreoni, 3, 4 Federico Pea, 1, 2 Pierluigi Viale 1, 5 1 Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy; 2 SSD Clinical Pharmacology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 3 Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy; 4 Infectious Diseases Clinic, University Hospital "Tor Vergata", Rome, Italy; 5 Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy Correspondence: Milo Gatti Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Via Massarenti 9, Bologna, 40138, Italy Tel +39 051 214 3627 Email Dalbavancin is a novel, long-acting lipoglycopeptide characterized by a long elimination half-life coupled with excellent in vitro activity against multidrug-resistant Gram-positives. Although it is currently approved only for the treatment of acute bacterial skin and skin structure infections, an ever-growing amount of evidence supports the efficacy of dalbavancin as a long-term therapy in osteomyelitis, prosthetic joint infections, endocarditis, and bloodstream infections. This article provides a critical reappraisal of real-world use of dalbavancin for off-label indications. A search strategy using specific keywords (dalbavancin, osteomyelitis, endocarditis, long-term suppressive therapy, bloodstream infection, pharmacokinetic/pharmacodynamic profile) until April 2021 was performed on the PubMed-MEDLINE database. As for other novel antibiotics, a conundrum between approved indications and potential innovative therapeutic uses has emerged for dalbavancin as well. The promising efficacy in challenging scenarios (i.e., osteomyelitis, endocarditis, prosthetic joint infections), coupled with the unique pharmacokinetic/pharmacodynamic properties, makes dalbavancin a valuable alternative to daily in-hospital intravenous or outpatient antimicrobial regimens in the treatment of long-term Gram-positive infections. This makes dalbavancin valuable in the current COVID-19 scenario, in which hospitalization and territorial medicine empowerment are unavoidable. Keywords: dalbavancin, osteomyelitis, endocarditis, long-term suppressive therapy, PK/PD properties, COVID-19 Dalbavancin is a novel, long-acting lipoglycopeptide active against Gram-positive pathogens, including multi-drug resistant isolates. 1 Long elimination half-life and good tissue penetration represent the main pharmacokinetic features of dalbavancin, 2 allowing for long-term efficacy despite the simplified weekly administration regimens. It was approved by the US Food and Drug Administration and the European Medicines Agency in 2014 and 2015 for the management of acute bacterial skin and skin structure infections (ABSSSIs) on an intravenous dosing regimen of 1500 mg as a single infusion or 1000 mg followed by 500 mg one week apart. 3 , 4 Currently, ABSSSIs remain the only approved indication for dalbavancin, although this could represent a non-innovative and inefficient exploitation of its pharmacokinetic/pharmacodynamic (PK/PD) properties. Indeed, as reported for other novel antibiotics (e.g., ceftazidime-avibactam), 5 a conundrum between approved indications and potential innovative therapeutic uses has emerged for dalbavancin. 6 An ever-growing amount of evidence supports the efficacy of dalbavancin as a long-term therapy for off-label indications, namely osteomyelitis, prosthetic joint infections, endocarditis, and bloodstream infections, 6–8 in which a treatment for at least 6 weeks is usually required. 9 , 10 In the current COVID-19 era, patients requiring prolonged antibiotic therapy after hospital discharge due to severe bacterial infections (e.g., endocarditis or osteomyelitis) are at increased risk for contracting and/or transmitting COVID-19 due to extensive contact with the healthcare system. 11 By virtue of its PK/PD properties, dalbavancin could be a valuable alternative to daily in-hospital intravenous or outpatient antimicrobial regimens in the treatment of long-term Gram-positive infections, providing an added value in the current COVID-19 scenario, in which ineluctable hospitalization and empowerment of territorial medicine are strongly required. We performed a critical reappraisal of real-world use of dalbavancin for off-label indications, suggesting th -Abstract Truncated-